TFPI-2 is a Kunitz-type serine protease inhibitor homologous to tissue factor pathway inhibitor (TFPI) (52,53), and its down-regulation in cancer has been proposed to contribute to tumour malignancy due its role in ECM remodelling. Here, TFPI is linked to neoplasm.